Research

Health Evidence Network Synthesis Report 73

Should the U.S. government be able to negotiate drug prices, and what is lost if they do.

The USC-Brookings Schaeffer Initiative for Health Policy hosted a webinar to discuss how the increasing reliance on rebates burdens many Medicare patients and the best policy solutions.

Duke-Margolis student voices.

This issue brief outlines just some of the ways that drug pricing reform would help consumers and businesses.

As new, high-priced drugs come to market and are covered under Medicare Part D, the current requirement for beneficiaries to pay a coinsurance of 5% in the catastrophic coverage phase can lead to thousands of dollars in out-of-pocket costs.

At $1.1 trillion, human health was by far the greatest driver of hidden food costs. It takes into account the share of direct medical costs attributable to diet as well as associated productivity loss.

Should drug prices differ by indication?

Racial inequity penetrates every corner of the American health care system, and high prescription drug prices are no exception.

The recent approval of Aduhelm (aducanumab), which treats Alzheimer’s disease and carries an expected annual price tag of $56,000, has brought increased attention to high-cost drugs approved through the FDA’s accelerated approval pathway.

Jointly issued by the American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the North American Association of Central Cancer Registries (NAACCR), and the National Cancer Institute (NCI).

An interesting new look at the interplay on the activities and policies of the drug industry and its stakeholders. 

For treating atopic dermatitis, health-benefit price benchmarks for these therapies range from $21,400 to $41,800 per year; upadacitinib requires the steepest discount - 35-63% - off its list price to reach common thresholds for cost-effectiveness.

Death rates are declining for more than half of the most common forms of cancer in the U.S., according to a sweeping annual analysis released Thursday.

Precision therapies are often approved based on small trials, in specialized settings, and using biomarkers as endpoints. Thus, despite their potential high cost, the evidence of value is lacking.